Published :
Tables : 63
Figures : 46
Category : Healthcare
No. of Pages : 230
Report Code : HC-U3262
Antiviral Drugs Market is predicted to value over USD xx billion by 2027 end with a CAGR of over xx% during the forecast period 2020 to 2027. Antiviral drugs are used for treating viral infections like hepatitis, influenza and HIV. These drugs are also used for treating respiratory syncytial virus which is why many companies are testing these drugs over the novel coronavirus, thereby increasing the antiviral drugs market demand. Rising prevalence of such viral infections shall prove to be a crucial factor contributing to the market growth. For example, as per the data provided by the WHO, over 880,000 deaths were caused due to hepatitis B is 2015. Furthermore, it was predicted that over 255 million patients were diagnosed with hepatitis B virus in 2015. Additionally, as per the weekly U.S. surveillance report on influenza that was published by the CDC, over 12 million flu cases were recorded in 2019. Such factors shall boost the antiviral drugs market growth. Furthermore, extensive research and development of advanced formulations like combination therapy shall further propel the market growth. However, the drug development process is expensive and alternative medicines like homeopathy and naturopathy are gaining significant demands which shall impede the market growth. Market Segmentation: By Drug Class DNA Polymerase Inhibitors Reverse Transcriptase Inhibitors Protease Inhibitors Neuraminidase Inhibitors Others By Type Branded Generic By Application HIV Hepatitis Herpes Influenza Others By Region North America Europe Asia-Pacific Latin America Middle East and Africa The reverse transcriptase inhibitors segment is predicted to account for the largest antiviral drugs market share owing to its capability of slowing down the infection in an effective manner. Some of the drugs used for treating HIV are Stavudine, Zalcitabine, Zidovudine, Nevirapine, Efavirenz, Didanosine and Etravirine. The branded segment led the market till 2019, but it is the generic segment that is predicted to dominate the market during the forecast period and this can be credited to a rising acceptance of generic drugs in emerging economies like India coupled with a large number of branded drugs with expired patents. Furthermore, many market players consider manufacturing generic drugs over branded ones as the overall process is cheaper, which shall boost the segment growth further. Hepatitis is further divided into hepatitis A, B and C and it is predicted to dominate the market owing to the availability of a large range of antiviral drugs like Tenofovir, Entecavir, Adefovir, Telbivudine and Lamivudine. The HIV segment is estimated to proliferate with a faster rate during the forecasted timeframe. There has been a strong pipeline of antiviral HIV drugs which shall boost the segment growth. For example, as per the data provided by UNAIDS, over 37 million people were diagnosed with HIV across the world in 2018. Such a rising prevalence shall boost drug development and in turn the market growth. Regional Analysis: The North America region is estimated to dominate the market and this is due to the availability of advanced healthcare infrastructure, rising awareness amongst the general population regarding viral diseases and ways in which they can be treated and a strong presence of key market players in the region. Competitive Landscape: Some of the prominent market players include Gilead Sciences, F. Hoffmann-La Roche AG, GlaxoSmithKline plc, AbbVie, Merck & Co. Inc., Johnson & Johnson Services Inc., Bristol-Myers Squibb Company, Cipla Inc., Aurobindo Pharma, Dr Reddy’s Laboratories Ltd., Glenmark Pharmaceuticals Ltd. Glenmark shall initiate the combined efficacy testing of two antiviral drugs, Umifenovir and Favipiravir. These drugs have a different set of action mechanism individually, but Glenmark is trying to demonstrate the improvements they can possibly show by combining and can help in tackling high patient count who are still in the early COVID-19 stages by improving their antiviral efficacy. FutureWise Key Takeaways: Growth prospects SWOT analysis Key market trends Key data-points affecting market growth Objectives of the Study: To provide with an exhaustive analysis on the global antiviral drugs market by type, by drug class, by application and by region To cater comprehensive information on factors impacting market growth (drivers, restraints, opportunities, and industry-specific restraints) To evaluate and forecast micro-markets and the overall market To predict the market size, in key regions (along with countries)— North America, Europe, Asia Pacific, Latin America and Middle East and Africa To record, evaluate and analyze competitive landscape mapping- product launches, technological advancements, mergers and expansions Flexible Delivery Model: We have a flexible delivery model and you can suggest changes in the scope/table of content as per your requirement The customization Mobility Care offered are free of charge with purchase of any license of the report You can directly share your requirements/changes to the current table of content to: sales@futurewiseresearch.com
Antiviral drugs are used for treating viral infections like hepatitis, influenza and HIV. These drugs are also used for treating respiratory syncytial virus which is why many companies are testing these drugs over the novel coronavirus, thereby increasing the antiviral drugs market demand. Rising prevalence of such viral infections shall prove to be a crucial factor contributing to the market growth. For example, as per the data provided by the WHO, over 880,000 deaths were caused due to hepatitis B is 2015.
Furthermore, it was predicted that over 255 million patients were diagnosed with hepatitis B virus in 2015. Additionally, as per the weekly U.S. surveillance report on influenza that was published by the CDC, over 12 million flu cases were recorded in 2019. Such factors shall boost the antiviral drugs market growth. Furthermore, extensive research and development of advanced formulations like combination therapy shall further propel the market growth. However, the drug development process is expensive and alternative medicines like homeopathy and naturopathy are gaining significant demands which shall impede the market growth.
Market Segmentation:
By Drug Class
By Type
By Application
By Region
The reverse transcriptase inhibitors segment is predicted to account for the largest antiviral drugs market share owing to its capability of slowing down the infection in an effective manner. Some of the drugs used for treating HIV are Stavudine, Zalcitabine, Zidovudine, Nevirapine, Efavirenz, Didanosine and Etravirine. The branded segment led the market till 2019, but it is the generic segment that is predicted to dominate the market during the forecast period and this can be credited to a rising acceptance of generic drugs in emerging economies like India coupled with a large number of branded drugs with expired patents. Furthermore, many market players consider manufacturing generic drugs over branded ones as the overall process is cheaper, which shall boost the segment growth further. Hepatitis is further divided into hepatitis A, B and C and it is predicted to dominate the market owing to the availability of a large range of antiviral drugs like Tenofovir, Entecavir, Adefovir, Telbivudine and Lamivudine. The HIV segment is estimated to proliferate with a faster rate during the forecasted timeframe. There has been a strong pipeline of antiviral HIV drugs which shall boost the segment growth. For example, as per the data provided by UNAIDS, over 37 million people were diagnosed with HIV across the world in 2018. Such a rising prevalence shall boost drug development and in turn the market growth.
Regional Analysis:
The North America region is estimated to dominate the market and this is due to the availability of advanced healthcare infrastructure, rising awareness amongst the general population regarding viral diseases and ways in which they can be treated and a strong presence of key market players in the region.
Competitive Landscape:
Some of the prominent market players include Gilead Sciences, F. Hoffmann-La Roche AG, GlaxoSmithKline plc, AbbVie, Merck & Co. Inc., Johnson & Johnson Services Inc., Bristol-Myers Squibb Company, Cipla Inc., Aurobindo Pharma, Dr Reddy’s Laboratories Ltd., Glenmark Pharmaceuticals Ltd.
Glenmark shall initiate the combined efficacy testing of two antiviral drugs, Umifenovir and Favipiravir. These drugs have a different set of action mechanism individually, but Glenmark is trying to demonstrate the improvements they can possibly show by combining and can help in tackling high patient count who are still in the early COVID-19 stages by improving their antiviral efficacy.
FutureWise Key Takeaways:
Objectives of the Study:
Flexible Delivery Model:
1. Market Introduction 1.1 Objectives of the Study 1.2 Market Definition 1.3 Market Scope 1.3.1 Years Considered for the Study 1.3.2 Market Covered 1.4 Currency 1.5 Limitations 1.6 Stakeholders 2. Research Methodology 2.1 Research Data 2.1.1 Secondary Data 2.1.1.1 Key Data from Secondary Sources 2.1.2 Primary Data 2.1.2.1 Key Data from Primary Sources 2.2 Market Size Estimation 2.3 Market Breakdown and Data Triangulation 2.4 Assumptions for the Study 3. Executive Summary 3.1 Market Outlook 3.2 Segment Outlook 3.3 Competitive Insights 4. Market Variables, Trends & Scope 4.1 Market Lineage Outlook 4.2 Penetration and Growth Prospect Mapping 4.3 Industry Value Chain Analysis 4.4 Cost Analysis Breakdown 4.5 Technology Overview 4.6 Regulatory Framework on Country Level 4.6.1 Reimbursement Framework 4.6.2 Standards and Compliances 5. Market Overview 5.1 Market Dynamics 5.1.1 Market Driver Analysis 5.1.1.1. Increasing focus of Antiviral Drugs Companies on Brand Protection 5.1.1.2. Untapped Opportunities in Emerging Regions 5.1.2 Market Restraint Analysis 5.1.2.1. High Cost Associated with Implementation of Predictive Analysis 5.1.3 Industry Challenges 5.1.3.1. Presence of Ambiguous Regulatory Framework 6. Market Analysis tools 6.1 Industry Analysis - Porter’s 6.1.1 Supplier Power 6.1.2 Buyer Power 6.1.3 Substitution Threat 6.1.4 Threat from new entrants 6.1.5 Competitive Rivalry 6.2 Pestel Analysis 6.2.1 Political Landscape 6.2.2 Environmental Landscape 6.2.3 Social landscape 6.2.4 Technology landscape 6.2.5 Legal Landscape 7. Antiviral Drugs Market, By Type Historical Analysis 2015 to 2019 and Forecast 2020-2027 (USD million) 7.1 Branded 7.2 Generic 8. Antiviral Drugs Market, By Drug Class Historical Analysis 2015 to 2019 and Forecast 2020-2027 (USD million) 8.1 DNA Polymerase Inhibitors 8.2 Reverse Transcriptase Inhibitors 8.3 Protease Inhibitors 8.4 Neuraminidase Inhibitors 8.5 Others 9. Antiviral Drugs Market, By Application Historical Analysis 2015 to 2019 and Forecast 2020-2027 (USD million) 9.1 HIV 9.2 Hepatitis 9.3 Herpes 9.4 Influenza 9.5 Others 10. North America Market Analysis 2015–2019 and Forecast 2020–2027 (USD Million) 10.1. Introduction 10.2. Historical Market Size (USD Mn) Analysis By Country, 2015-2019 10.2.1. U.S. 10.2.2. Canada 10.2.3. Mexico 10.2.4 Rest of North America 10.3 Market Size (USD Mn) Forecast for North America 2020-2027 11. Latin America Market Analysis 2015–2019 and Forecast 2020–2027 (USD Million) 11.1. Introduction 11.2. Regional Market Trends 11.3. Historical Market Size (US$ Mn) Analysis By Country, 2015-2019 11.3.1. Brazil 11.3.2. Uruguay 11.3.3 Argentina 11.3.4. Rest of Latin America 11.4 Market Size (US$ Mn) Forecast for Latin America 2020-2027 12. Europe Market Analysis 2015–2019 and Forecast 2020–2027 (USD Million) 12.1. Introduction 12.2. Historical Market Size (US$ Mn) Analysis By Country, 2015-2019 12.2.1. Germany 12.2.2. U.K 12.2.3. France 12.2.4. Italy 12.2.5 Switzerland 12.2.6. Spain 12.2.7. Russia 12.2.8. Poland 12.2.9. Rest of Western Europe 12.3 Market Size (US$ Mn) Forecast for Europe 2020-2027 13. Asia Pacific Market Analysis 2015–2019 and Forecast 2020–2027 (USD Million) 13.1 Introduction 13.2 Historical Market Size (USD Mn) Analysis By Country, 2015-2019 13.2.1 Japan 13.2.2 China 13.2.3 Singapore 13.2.4 Korea 13.2.5 India 13.2.6 Australia and New Zealand 13.2.7 ASEAN 13.2.8 Rest of Asia Pacific 13.3 Market Size (US$ Mn) Forecast for Asia Pacific 2020-2027 14. Middle East and Africa Market Analysis 2015–2019 and Forecast 2020–2027 (USD Million) 14.1 Introduction 14.2 Historical Market Size (USD Mn) Analysis By Country, 2015-2019 14.2.1 UAE 14.2.2 South Africa 14.2.3 Egypt 14.2.4 Saudi Arabia 14.2.5 Rest of MEA 14.3 Market Size (US$ Mn) Forecast for MEA 2020-2027 15. Company Profiles (Competition Dashboard, Competitors Deep Dive, Product Type and Technology Portfolio, Financial Layouts) 15.1 Gilead Sciences 15.1.1. Company Overview (HQ, Business Segments, Employee Strength) 15.1.2. Product Portfolio 15.1.3. SWOT Analysis 15.1.4. Financial Overview 15.1.5. Strategic Overview 15.2 F. Hoffmann-La Roche AG 15.2.1. Company Overview (HQ, Business Segments, Employee Strength) 15.2.2. Product Portfolio 15.2.3. SWOT Analysis 15.2.4. Financial Overview 15.2.5. Strategic Overview 15.3 GlaxoSmithKline plc 15.3.1. Company Overview (HQ, Business Segments, Employee Strength) 15.3.2. Product Portfolio 15.3.3. SWOT Analysis 15.3.4. Financial Overview 15.3.5. Strategic Overview 15.4 AbbVie 15.4.1. Company Overview (HQ, Business Segments, Employee Strength) 15.4.2. Product Portfolio 15.4.3. SWOT Analysis 15.4.4. Financial Overview 15.4.5. Strategic Overview 15.5 Merck & Co. Inc. 15.5.1. Company Overview (HQ, Business Segments, Employee Strength) 15.5.2. Product Portfolio 15.5.3. SWOT Analysis 15.5.4. Financial Overview 15.5.5. Strategic Overview 15.6 Johnson & Johnson Services Inc. 15.6.1. Company Overview (HQ, Business Segments, Employee Strength) 15.6.2. Product Portfolio 15.6.3. SWOT Analysis 15.6.4. Financial Overview 15.6.5. Strategic Overview 15.7 Bristol-Myers Squibb Company 15.7.1. Company Overview (HQ, Business Segments, Employee Strength) 15.7.2. Product Portfolio 15.7.3. SWOT Analysis 15.7.4. Financial Overview 15.7.5. Strategic Overview 15.8 Cipla Inc. 15.8.1. Company Overview (HQ, Business Segments, Employee Strength) 15.8.2. Product Portfolio 15.8.3. SWOT Analysis 15.8.4. Financial Overview 15.8.5. Strategic Overview 15.9 Aurobindo Pharma 15.9.1. Company Overview (HQ, Business Segments, Employee Strength) 15.9.2. Product Portfolio 15.9.3. SWOT Analysis 15.9.4. Financial Overview 15.9.5. Strategic Overview 15.10 Dr Reddy’s Laboratories Ltd. 15.10.1. Company Overview (HQ, Business Segments, Employee Strength) 15.10.2. Product Portfolio 15.10.3. SWOT Analysis 15.10.4. Financial Overview 15.10.5. Strategic Overview 16 Impact of COVID-19 16.1. Positive influence on the healthcare industry 16.2. The financial disruption of the manufacturing sector 16.3. Impact of COVID-19 on emerging companies 16.4. Significant mandates in the healthcare regulations initiated by administrations 16.5. The overall economic slowdown of the developing and developed nations 17. Competitive Intelligence and Competitive Matrix 17.1 Competitive Intelligence 17.2 Competitive Matrix 18. Major Deals and Strategic Alliances Analysis 18.1 Joint ventures 18.2 Mergers and acquisitions 18.3 Licensing and partnerships 18.4 Technology Collaborations 18.5 Strategic Divestments 18.6 Market Entry Strategies 19. Relevant Case Studies and Latest News Updates 20. Key Market Takeaway Points from the Market Analysts at Future Market Analytics
1. Market Introduction 1.1 Objectives of the Study 1.2 Market Definition 1.3 Market Scope 1.3.1 Years Considered for the Study 1.3.2 Market Covered 1.4 Currency 1.5 Limitations 1.6 Stakeholders
2. Research Methodology 2.1 Research Data 2.1.1 Secondary Data 2.1.1.1 Key Data from Secondary Sources 2.1.2 Primary Data 2.1.2.1 Key Data from Primary Sources 2.2 Market Size Estimation 2.3 Market Breakdown and Data Triangulation 2.4 Assumptions for the Study
3. Executive Summary 3.1 Market Outlook 3.2 Segment Outlook 3.3 Competitive Insights
4. Market Variables, Trends & Scope 4.1 Market Lineage Outlook 4.2 Penetration and Growth Prospect Mapping 4.3 Industry Value Chain Analysis 4.4 Cost Analysis Breakdown 4.5 Technology Overview 4.6 Regulatory Framework on Country Level 4.6.1 Reimbursement Framework 4.6.2 Standards and Compliances
5. Market Overview 5.1 Market Dynamics 5.1.1 Market Driver Analysis 5.1.1.1. Increasing focus of Antiviral Drugs Companies on Brand Protection 5.1.1.2. Untapped Opportunities in Emerging Regions 5.1.2 Market Restraint Analysis 5.1.2.1. High Cost Associated with Implementation of Predictive Analysis 5.1.3 Industry Challenges 5.1.3.1. Presence of Ambiguous Regulatory Framework
6. Market Analysis tools 6.1 Industry Analysis - Porter’s 6.1.1 Supplier Power 6.1.2 Buyer Power 6.1.3 Substitution Threat 6.1.4 Threat from new entrants 6.1.5 Competitive Rivalry 6.2 Pestel Analysis 6.2.1 Political Landscape 6.2.2 Environmental Landscape 6.2.3 Social landscape 6.2.4 Technology landscape 6.2.5 Legal Landscape
7. Antiviral Drugs Market, By Type Historical Analysis 2015 to 2019 and Forecast 2020-2027 (USD million) 7.1 Branded 7.2 Generic
8. Antiviral Drugs Market, By Drug Class Historical Analysis 2015 to 2019 and Forecast 2020-2027 (USD million) 8.1 DNA Polymerase Inhibitors 8.2 Reverse Transcriptase Inhibitors 8.3 Protease Inhibitors 8.4 Neuraminidase Inhibitors 8.5 Others
9. Antiviral Drugs Market, By Application Historical Analysis 2015 to 2019 and Forecast 2020-2027 (USD million) 9.1 HIV 9.2 Hepatitis 9.3 Herpes 9.4 Influenza 9.5 Others
10. North America Market Analysis 2015–2019 and Forecast 2020–2027 (USD Million) 10.1. Introduction 10.2. Historical Market Size (USD Mn) Analysis By Country, 2015-2019 10.2.1. U.S. 10.2.2. Canada 10.2.3. Mexico 10.2.4 Rest of North America 10.3 Market Size (USD Mn) Forecast for North America 2020-2027
11. Latin America Market Analysis 2015–2019 and Forecast 2020–2027 (USD Million) 11.1. Introduction 11.2. Regional Market Trends 11.3. Historical Market Size (US$ Mn) Analysis By Country, 2015-2019 11.3.1. Brazil 11.3.2. Uruguay 11.3.3 Argentina 11.3.4. Rest of Latin America 11.4 Market Size (US$ Mn) Forecast for Latin America 2020-2027
12. Europe Market Analysis 2015–2019 and Forecast 2020–2027 (USD Million) 12.1. Introduction 12.2. Historical Market Size (US$ Mn) Analysis By Country, 2015-2019 12.2.1. Germany 12.2.2. U.K 12.2.3. France 12.2.4. Italy 12.2.5 Switzerland 12.2.6. Spain 12.2.7. Russia 12.2.8. Poland 12.2.9. Rest of Western Europe 12.3 Market Size (US$ Mn) Forecast for Europe 2020-2027
13. Asia Pacific Market Analysis 2015–2019 and Forecast 2020–2027 (USD Million) 13.1 Introduction 13.2 Historical Market Size (USD Mn) Analysis By Country, 2015-2019 13.2.1 Japan 13.2.2 China 13.2.3 Singapore 13.2.4 Korea 13.2.5 India 13.2.6 Australia and New Zealand 13.2.7 ASEAN 13.2.8 Rest of Asia Pacific 13.3 Market Size (US$ Mn) Forecast for Asia Pacific 2020-2027
14. Middle East and Africa Market Analysis 2015–2019 and Forecast 2020–2027 (USD Million) 14.1 Introduction 14.2 Historical Market Size (USD Mn) Analysis By Country, 2015-2019 14.2.1 UAE 14.2.2 South Africa 14.2.3 Egypt 14.2.4 Saudi Arabia 14.2.5 Rest of MEA 14.3 Market Size (US$ Mn) Forecast for MEA 2020-2027
15. Company Profiles (Competition Dashboard, Competitors Deep Dive, Product Type and Technology Portfolio, Financial Layouts) 15.1 Gilead Sciences 15.1.1. Company Overview (HQ, Business Segments, Employee Strength) 15.1.2. Product Portfolio 15.1.3. SWOT Analysis 15.1.4. Financial Overview 15.1.5. Strategic Overview 15.2 F. Hoffmann-La Roche AG 15.2.1. Company Overview (HQ, Business Segments, Employee Strength) 15.2.2. Product Portfolio 15.2.3. SWOT Analysis 15.2.4. Financial Overview 15.2.5. Strategic Overview 15.3 GlaxoSmithKline plc 15.3.1. Company Overview (HQ, Business Segments, Employee Strength) 15.3.2. Product Portfolio 15.3.3. SWOT Analysis 15.3.4. Financial Overview 15.3.5. Strategic Overview 15.4 AbbVie 15.4.1. Company Overview (HQ, Business Segments, Employee Strength) 15.4.2. Product Portfolio 15.4.3. SWOT Analysis 15.4.4. Financial Overview 15.4.5. Strategic Overview 15.5 Merck & Co. Inc. 15.5.1. Company Overview (HQ, Business Segments, Employee Strength) 15.5.2. Product Portfolio 15.5.3. SWOT Analysis 15.5.4. Financial Overview 15.5.5. Strategic Overview 15.6 Johnson & Johnson Services Inc. 15.6.1. Company Overview (HQ, Business Segments, Employee Strength) 15.6.2. Product Portfolio 15.6.3. SWOT Analysis 15.6.4. Financial Overview 15.6.5. Strategic Overview 15.7 Bristol-Myers Squibb Company 15.7.1. Company Overview (HQ, Business Segments, Employee Strength) 15.7.2. Product Portfolio 15.7.3. SWOT Analysis 15.7.4. Financial Overview 15.7.5. Strategic Overview 15.8 Cipla Inc. 15.8.1. Company Overview (HQ, Business Segments, Employee Strength) 15.8.2. Product Portfolio 15.8.3. SWOT Analysis 15.8.4. Financial Overview 15.8.5. Strategic Overview 15.9 Aurobindo Pharma 15.9.1. Company Overview (HQ, Business Segments, Employee Strength) 15.9.2. Product Portfolio 15.9.3. SWOT Analysis 15.9.4. Financial Overview 15.9.5. Strategic Overview 15.10 Dr Reddy’s Laboratories Ltd. 15.10.1. Company Overview (HQ, Business Segments, Employee Strength) 15.10.2. Product Portfolio 15.10.3. SWOT Analysis 15.10.4. Financial Overview 15.10.5. Strategic Overview
16 Impact of COVID-19 16.1. Positive influence on the healthcare industry 16.2. The financial disruption of the manufacturing sector 16.3. Impact of COVID-19 on emerging companies 16.4. Significant mandates in the healthcare regulations initiated by administrations 16.5. The overall economic slowdown of the developing and developed nations
17. Competitive Intelligence and Competitive Matrix 17.1 Competitive Intelligence 17.2 Competitive Matrix
18. Major Deals and Strategic Alliances Analysis 18.1 Joint ventures 18.2 Mergers and acquisitions 18.3 Licensing and partnerships 18.4 Technology Collaborations 18.5 Strategic Divestments 18.6 Market Entry Strategies
19. Relevant Case Studies and Latest News Updates
20. Key Market Takeaway Points from the Market Analysts at Future Market Analytics
UK : +44 141 628 9353 US : +1 347 709 4931
OR
Excel Dataset
Infographics
PDF Report
Market Overview
PowerPoint Presentation
Consumer Perception and Procurement
Competitive Analysis
What’s Next
Market Data Forecast
Risks and Opportunity Assessment
Market Trends and Dynamics